

**Table S3** IC<sub>50</sub> values of **126–165** against cancer and normal cell lines, at different incubation time, mechanism of action, target and cell cycle arrest.

Complex number	Cell line/IC <sub>50</sub> (μM) <sup>1,2</sup>					Mechanism of action	Cell Cycle arrest	Target	Ref.
<b>3.4. Polynuclear half-sandwich Ir(III) complexes</b>									
<b>3.4.1. N or P-ligands</b>									
<b>126a</b> *	A2780	101.9	A2780cisR	> 200	HEK-293T <sup>(N)</sup>	118.8		n.d	281
<b>126b</b> *		97.0		45.5		148.5			
<b>127a</b>	WHCO1		111.5 ± 4.2				n.d	DNA	282
<b>127b</b>			48.3 ± 8.8						
<b>3.4.2. C^N ligands</b>									
<b>128a</b>	A2780	29.7 ± 0.1	A2780cisR	28.1 ± 2.0	HEK-293T <sup>(N)</sup>	n.d		n.d	283
<b>128b</b> <sup>T</sup>		13.7 ± 0.1		3.0 ± 0.2		5.0 ± 1.2			
<b>128c</b> <sup>T</sup>		20.1 ± 13.6		19.0 ± 8.5		72.4 ± 91.1			
<b>3.4.3. N^N and N^O ligands</b>									
<b>129a</b>	MCF-7 (Crystal violet); 3.5			HT-29 (Crystal violet); 1.8		DNA (mono-intercalation)	n.d	DNA	285
<b>129b</b>	n.d								
<b>129c</b>	MCF-7		3.1	HT-29		3.8		DNA (bis-intercalation)	
<b>129d</b>			0.109			n.d			
<b>130a</b>	MCF-7 (Crystal violet)		0.61	HT-29 (Crystal violet)		3.7	n.d	DNA (mono-intercalation)	123
<b>130b</b>			7.9			12.7			
<b>130c</b>			0.49			2.5		DNA (mono-intercalation)	
<b>130d</b>			3.8			4.2			
<b>130e</b>			2.2			5.1		DNA (bis-intercalation)	
<b>130f</b>			3.8			4.4			
<b>131a</b>	B16F10; 10.75 ± 1.3			PC3; 13.26 ± 1.6			n.d		287
	THP1; 18.93 ± 2.5			SKOV-3; 15.12 ± 1.7					
<b>131b</b>	B16F10; 40.32 ± 2.4			PC3; 34.14 ± 2.1					

	THP1; n.d			SKOV-3; n.d						
<b>131c</b>	B16F10; n.d			PC3; 43.81 ± 2.6						
	THP1; n.d			SKOV-3; n.d						
<b>132a</b>	n.d						Apoptosis	n.d		288
<b>132b</b>										
<b>132c</b>										
<b>133a</b>	HeLa (WST-1)	32.72 ± 2.19	U87 (WST-1)	23.94 ± 1.91	WI 30 (WST-1)	589.57 ± 31.78	DNA interaction		Cytoplasm	289
<b>133b</b>		39.99 ± 1.29		57.56 ± 2.32		89.04 ± 8.78				
<b>134a</b> <sup>T</sup>	HT-29; 52.17 ± 4.78			HCT-116p53 <sup>-/-</sup> ; 46.88 ± 2.15				n.d		290
	HCT-116p53 <sup>+/+</sup> ; 41.08 ± 17.74			ARPE-19 <sup>(N)</sup> ; 60.65 ± 4.78						
<b>134b</b> <sup>T</sup>	HT-29; 18.03 ± 3.26			HCT-116p53 <sup>-/-</sup> ; 18.43 ± 0.24						
	HCT-116p53 <sup>+/+</sup> ; 19.26 ± 0.81			ARPE-19 <sup>(N)</sup> ; 38.82 ± 13.68						
<b>134c</b> <sup>*</sup>	HT-29; 53.51 ± 2.79			HCT-116p53 <sup>-/-</sup> ; 58.00 ± 5.56						
	HCT-116p53 <sup>+/+</sup> ; 57.84 ± 2.89			ARPE-19 <sup>(N)</sup> ; >100						
<b>134d</b> <sup>*</sup>	HT-29; 37.32 ± 2.54			HCT-116p53 <sup>-/-</sup> ; 57.19 ± 0.50						
	HCT-116p53 <sup>+/+</sup> ; 52.63 ± 4.96			ARPE-19 <sup>(N)</sup> ; >100						
<b>135a</b>	A2780; 34.2 ± 0.6		MCF-7; > 50		HT-29; > 50			n.d		291
	A2780R; > 50		HOS; > 50		PANC-1; > 50					
<b>135b</b>	A2780; 3.1 ± 0.1		MCF-7; 6.0 ± 0.2		HT-29; 25.7 ± 1.4		ROS/RNS/Apoptosis	G <sub>2</sub> /M	Mitochondria	
	A2780R; 3.8 ± 0.4		HOS; 6.8 ± 1.9		PANC-1; 7.4 ± 1.2					
<b>136a</b>	MCF-7; > 25		HepG2; > 25		A375; > 25		NADH	n.d		292
	A549; > 25		DU-145; > 25							
<b>136b</b>	MCF-7; > 25		HepG2; 12.6		A375; > 25					
	A549; 16.5		DU-145; >25							
<b>136c</b>	MCF-7; > 25		HepG2; > 25		A375; > 25					
	A549; > 25		DU-145; > 25							
<b>137</b>	n.d							n.d		293
<b>138a</b>	A2780	40 ± 2	A2780cisR	60 ± 6	HEK-293T <sup>(N)</sup>	n.d				294
<b>138b</b> <sup>T</sup>		2.6 ± 0.5		8.9 ± 1.2		10.2 ± 0.5				
<b>138c</b> <sup>T</sup>		0.75 ± 0.01		3.5 ± 0.3		28.6 ± 1.3				
<b>138d</b>		66 ± 5.2		33.8 ± 3.8		n.d				
<b>138e</b>		40 ± 3		48 ± 4		n.d				
<b>138f</b>		55.1 ± 0.2		49.0 ± 1.6		n.d				
<b>139a</b>		11.58 ± 4.35		41.45 ± 3.28		84.40 ± 1.16		n.d		295

<b>139b</b>	A2780 (WST-1)	30.79 ± 1.16	A2780cisR (WST-1)	50.49 ± 3.08	KMST-6 (WST-1)	85.04 ± 3.64				
<b>139c</b>		141.88 ± 1.19		80.20 ± 1.71		100.54 ± 5.01				
<b>139d</b>		107.00 ± 3.95		109.91 ± 5.92		116.20 ± 4.35				
<b>140a</b>	WHCO1	> 300					n.d		296	
<b>140b</b>		58.0 ± 19.3					n.d		297	
<b>140c</b>		59.6 ± 23.7								
<b>140d</b>		49.5 ± 19.0								
<b>140e</b>		> 270								
<b>141a</b>		200.8 ± 9.9					n.d		296	
<b>141b</b>		13.0 ± 9.0					n.d		297	
<b>141c</b>		6.2 ± 4.5								
<b>141d</b>		9.6 ± 4.6								
<b>141e</b>		49.5 ± 16.7								
<b>3.4.4. O<sup>+</sup>O ligands</b>										
<b>142a<sup>T</sup></b>	A2780	0.07 ± 0.01	A2780cisR	0.25 ± 0.05	HEK-293T <sup>(N)</sup>	0.09 ± 0.02		n.d		298
<b>142b<sup>T</sup></b>		0.13 ± 0.02		0.31 ± 0.04		0.11 ± 0.02				
<b>142c<sup>T</sup></b>		0.17 ± 0.01		0.29 ± 0.03		0.10 ± 0.02				
<b>143a<sup>T</sup></b>	DU-145; 16.0 ± 0.4		HeLa; 4.16 ± 0.3			n.d	n.d	DNA	299	
	A549; 3.18 ± 0.2		HEK-293T <sup>(N)</sup> ; 31.2 ± 0.5							
<b>143b<sup>T</sup></b>	DU-145; 2.53 ± 0.2		HeLa; 1.04 ± 0.3							
	A549; 0.84 ± 0.1		HEK-293T <sup>(N)</sup> ; 40.3 ± 0.4							
<b>143c<sup>T</sup></b>	DU-145; 0.72 ± 0.2		HeLa; 0.59 ± 0.2				Sub-G <sub>1</sub>			
	A549; 0.67 ± 0.4		HEK-293T <sup>(N)</sup> ; 70.8 ± 0.4							
<b>144<sup>T</sup></b>	MCF-7; 1.0 ± 0.2	A549; 0.7 ± 0.2		CRL-2120 <sup>(N)</sup> ; 1.2 ± 0.2			n.d		300	
	B16F10; 0.8 ± 0.3	CRL-2115 <sup>(N)</sup> ; 1.2 ± 0.3								
<b>145<sup>T</sup></b>	MCF-7; 0.7 ± 0.2	A549; 0.7 ± 0.4		CRL-2120 <sup>(N)</sup> ; 1.1 ± 0.4		ROS (irradiation with UV)/DNA Cleavage/ MMP/Apoptosis	sub-G <sub>1</sub>	Mitochondria		
	B16F10; 0.7 ± 0.4	CRL-2115 <sup>(N)</sup> ; 1.1 ± 0.4								
<b>146a</b>	A549 (WST-1); 59.88 ± 2.69	HeLa (WST-1); 42.39 ± 3.34		WI-38 (WST-1); 11.67 ± 0.11		ROS	sub-G <sub>1</sub>	DNA	301	
	MCF-7 (WST-1); 3.79 ± 0.12	U87 (WST-1); 61.45 ± 3.64								
<b>146b</b>	A549 (WST-1); 3.30 ± 0.14		HeLa (WST-1); 2.22 ± 0.07		WI-38 (WST-1); 2.10 ± 0.17					

	MCF-7 (WST-1); 1.82 ± 0.06		U87 (WST-1); 0.54 ± 0.07						
<b>146c</b>	HeLa (WST-1)	> 500	U87 (WST-1)	> 400	WI-38 (WST-1)	93.79 ± 8.45	n.d	DNA	302
<b>146d</b>		2.13 ± 0.16		2.83 ± 0.13		2.80 ± 0.13			
<b>147a</b>		> 4000		> 900		> 900			
<b>147b</b>		11.65 ± 0.81		8.28 ± 0.09		7.01 ± 0.21			
<b>148a</b>	HT-29 (24h)		1.0 ± 0.1	HT-29 (48h);		0.8 ± 0.1	n.d	ROS	303
<b>148b</b>			0.8 ± 0.1			0.6 ± 0.1			
<b>149<sup>*</sup> (A)</b>	MCF-7; 86 ± 4			A549; 82 ± 4			n.d		304
	B16; 71 ± 4			NIH 3T3 <sup>(N)</sup> ; 116 ± 5					
<b>150a<sup>T</sup></b>	A549; 4.0 ± 0.4			Hela; 4.0 ± 0.6			n.d		305
	MCF-7; 3.0 ± 0.4			NIH 3T3 <sup>(N)</sup> ; 5.0 ± 1.4					
<b>150b<sup>T</sup></b>	A549; 3.0 ± 0.4			Hela; 2.0 ± 0.3			MMP/Apoptosis	Sub-G <sub>1</sub>	Mitochondria\ ds-DNA intercalation
	MCF-7; 1.3 ± 0.3			NIH 3T3 <sup>(N)</sup> ; 1.0 ± 0.8					
<b>150c<sup>T</sup></b>	A549; 5.0 ± 0.8			Hela; 4.0 ± 0.6			n.d		
	MCF-7; 4.0 ± 0.7			NIH 3T3 <sup>(N)</sup> ; 4.0 ± 0.6					
<b>151a</b>	n.d								
<b>151b</b>									
<b>151c</b>									
<b>151d</b>	HCT-116 (SRB); 0.38 ± 0.04			SiHa (SRB); 0.75 ± 0.1			S phase		306
	NCI-H460 (SRB); 0.21 ± 0.05			SW480 (SRB); 0.88 ± 0.09					
<b>• Chalcogen</b>									
<b>152a<sup>*</sup></b>	BE; 23.13 ± 3.83			MIA-Pa-Ca2; > 100			n.d		307
	HT-29; > 100			ARPE-19 <sup>(N)</sup> ; > 100					
<b>152b<sup>T</sup></b>	BE; 36.29 ± 8.68			MIA-Pa-Ca2; 17.12 ± 4.58					
	HT-29; 49.55 ± 2.97			ARPE-19 <sup>(N)</sup> ; 59.71 ± 1.75					
<b>153a<sup>T</sup></b>	A549	7.44 ± 1.05	HeLa	6.43 ± 1.02	BEAS-2B <sup>(N)</sup>	13.01 ± 0.33	n.d		308
<b>153b<sup>T</sup></b>		12.56 ± 0.05		10.46 ± 0.50		24.60 ± 0.23			
<b>153c<sup>T</sup></b>		4.98 ± 0.15		5.43 ± 0.49		9.98 ± 0.45			
<b>153d<sup>T</sup></b>		3.79 ± 1.15		6.43 ± 0.01		11.50 ± 0.31			
<b>154a<sup>*</sup></b>	0.442 ± 6		B16F10; 0.319 ± 5		MCF-7; 0.582 ± 6		ROS/Apoptosis	G <sub>2</sub>	DNA
	CRL-2115 <sup>(N)</sup> ; 1.024 ± 5		CRL-2120 <sup>(N)</sup> ; 1.136 ± 4						
<b>154b<sup>*</sup></b>	A549; 0.472 ± 5		B16F10; 0.358 ± 6		MCF-7; 0.597 ± 7		n.d		

	CRL-2115 <sup>(N)</sup> ; 1.037 ± 7		CRL-2120 <sup>(N)</sup> ; 1.232 ± 6								
<b>154c</b> *	A549; 0.456 ± 4		B16F10; 0.341 ± 5	MCF-7; 0.587 ± 4							
	CRL-2115 <sup>(N)</sup> ; 1.025 ± 8		CRL-2120 <sup>(N)</sup> ; 1.187 ± 8								
<b>154d</b> *	A549; 0.453 ± 5		B16F10; 0.354 ± 7	MCF-7; 0.568 ± 6							
	CRL-2115 <sup>(N)</sup> ; 1.028 ± 7		CRL-2120 <sup>(N)</sup> ; 1.254 ± 7								
<b>154e</b> *	A549; 0.446 ± 6		B16F10; 0.346 ± 5	MCF-7; 0.552 ± 5							
	CRL-2115 <sup>(N)</sup> ; 1.017 ± 8		CRL-2120 <sup>(N)</sup> ; 1.215 ± 6								
<b>155a</b> <sup>T</sup>	A2780	0.09 ± 0.01	A2780cisR	0.06 ± 0.01	HEK-293T <sup>(N)</sup>	0.08 ± 0.01			310		
<b>155b</b> <sup>T</sup>		0.11 ± 0.02		0.06 ± 0.01		0.09 ± 0.02					
<b>155c</b> <sup>T</sup>		0.43 ± 0.01		0.66 ± 0.05		1.24 ± 0.06					
<b>156a</b> <sup>T</sup>	A2780	0.07 ± 0.01	HEK-293T <sup>(N)</sup>	0.03 ± 0.01				311			
<b>156b</b> <sup>T</sup>		0.04 ± 0.01		0.03 ± 0.01							
<b>156c</b> <sup>T</sup>		0.06 ± 0.01		0.03 ± 0.01							
<b>156d</b> <sup>T</sup>		0.05 ± 0.01		0.08 ± 0.01							
<b>156e</b> <sup>T</sup>		0.03 ± 0.01		0.07 ± 0.01							
• Ferrocene											
<b>157a</b>	A549	50.09 ± 0.12	HeLa	75.56 ± 1.20	BEAS-2B <sup>(N)</sup>	82.51 ± 1.33			143		
<b>157b</b> *		59.88 ± 0.08		77.90 ± 1.03		> 100					
<b>157c</b> <sup>T</sup>		27.58 ± 0.23		19.89 ± 1.09		73.11 ± 1.17	G <sub>2</sub> /M				
<b>157d</b> *		41.28 ± 0.10		22.47 ± 0.63		> 100					
<b>157e</b> <sup>T</sup>		6.03 ± 0.05		9.50 ± 0.56		33.85 ± 0.35	<b>2B</b>	G <sub>1</sub> /G <sub>0</sub>		Lysosome	
<b>157f</b> <sup>T</sup>		8.52 ± 0.18		9.86 ± 0.96		47.85 ± 0.19	<b>2B</b>				
<b>158a</b> <sup>T</sup>	A549	8.44 ± 0.59	A549/DDP	14.57 ± 0.98	BEAS-2B <sup>(N)</sup>	27.16 ± 0.96	<b>1B</b>	G <sub>1</sub> /G <sub>0</sub>	Lysosome	312	
<b>158b</b> <sup>T</sup>		12.19 ± 0.92		12.48 ± 1.05		31.50 ± 0.61	n.d.				
<b>159a</b> <sup>T</sup>		30.34 ± 4.88	HeLa	21.42 ± 0.81		33.48 ± 0.41	<b>1B</b>	n.d.	G <sub>2</sub> /M phase	Lysosome	313
<b>159b</b> <sup>T</sup>		19.90 ± 0.66		13.90 ± 0.79		23.66 ± 0.72					
<b>159c</b> <sup>T</sup>		6.70 ± 0.40		7.42 ± 0.41		8.06 ± 0.03					
<b>159d</b> <sup>T</sup>		4.81 ± 0.27		5.51 ± 0.10		7.32 ± 0.42					
<b>160</b>	DI; > 110					Apoptosis	n.d.	DNA	315		
<b>161a</b> <sup>T</sup>	46.4 ± 2.5		59.0 ± 0.6		35.9 ± 3.4		n.d.		316		

<b>161b</b> <sup>T</sup>	A2780	11.7 ± 0.3	A2780cisR	7.6 ± 1.3	HEK-293T <sup>(N)</sup>	13.6 ± 2.0				
<b>161c</b> <sup>T</sup>		39.6 ± 3.0		36.7 ± 0.2		31.1 ± 0.3				
<b>162a</b> <sup>T</sup>	A549	33.1 ± 1.6	HeLa	13.1 ± 0.6	BEAS-2B <sup>(N)</sup>	12.5 ± 1.6		n.d		75
<b>162b</b> <sup>T</sup>		18.1 ± 1.2		12.5 ± 0.5		12.3 ± 0.9				
<b>162c</b> <sup>T</sup>		8.9 ± 1.7		10.5 ± 0.5		10.3 ± 2.3	<b>2A</b>	G <sub>0</sub> /G <sub>1</sub>	Mitochondria	
<b>• Heteronuclear</b>										
<b>163a</b> <sup>*</sup>	Caco-2	11 ± 1.0	HeLa	23.4 ± 0.9	HEK-293T <sup>(N)</sup>	> 200	MMP/Apoptosis	G <sub>2</sub> /M	Mitochondria & DNA	318
<b>163b</b> <sup>*</sup>		23 ± 2.1		> 100		> 200		n.d		
<b>163c</b> <sup>*</sup>		8 ± 0.8		70.5 ± 0.8		> 200				
<b>163d</b> <sup>*</sup>		2.2 ± 0.4		14.2 ± 1.2		> 200	MMP/Apoptosis	G <sub>2</sub> /M	Mitochondria & DNA	
<b>164a</b> <sup>*</sup>	A549; 35.5 ± 5.6 × 10 <sup>-3</sup>	MCF-7; 35.3 ± 6.5		DU-145; 12.8 ± 2.7 × 10 <sup>-7</sup>		Apoptosis	S phase	Nuclei	319	
24h	WM2664; 5.2 ± 4.1 × 10 <sup>-3</sup>	HEK-293T <sup>(N)</sup> ; 786.8 ± 11.2								
<b>164a</b> <sup>*</sup>	A549; 42.4 ± 7.3 × 10 <sup>-5</sup>	MCF-7; > 1000		DU-145; 125.7 ± 3.4						
72h	WM2664; 137.1 ± 2.2	HEK-293T <sup>(N)</sup> ; 886.8 ± 12.7								
<b>164b</b> <sup>*</sup>	A549; 11.2 ± 7.8 × 10 <sup>-3</sup>	MCF-7; 30.0 ± 0.7		DU-145; 10.8 ± 1.9 × 10 <sup>-4</sup>						
24h	WM2664; 9.9 ± 3.8 × 10 <sup>-3</sup>	HEK-293T <sup>(N)</sup> ; 756.8 ± 5.7								
<b>164b</b> <sup>*</sup>	A549; 36.6 ± 2.8 × 10 <sup>-3</sup>	MCF-7; > 1000		DU-145; 122.7 ± 5.4						
72h	WM2664; 155.1 ± 3.2	HEK-293T <sup>(N)</sup> ; 856.8 ± 15.9								
<b>164c</b> <sup>*</sup>	A549; 31.6 ± 7.6 × 10 <sup>-3</sup>	MCF-7; 24.2 ± 7.2		DU-145; 14.2 ± 2.4 × 10 <sup>-3</sup>						
24h	WM2664; 10.1 ± 2.2 × 10 <sup>3</sup>	HEK-293T <sup>(N)</sup> ; 775.8 ± 15.7								
<b>164c</b> <sup>*</sup>	A549; 36.0 ± 2.2 × 10 <sup>-2</sup>	MCF-7; > 1000		DU-145; 126.2 ± 4.4						
72h	WM2664; 229.3 ± 25.9	HEK-293T <sup>(N)</sup> ; 822.8 ± 12.3								
<b>164d</b> <sup>*</sup>	A549; 18.1 ± 1.3 × 10 <sup>-3</sup>	MCF-7; 10.5 ± 0.8		DU-145; 10.1 ± 2.9 × 10 <sup>-3</sup>						
24h	WM2664; 6.2 ± 2.4 × 10 <sup>-3</sup>	HEK-293T <sup>(N)</sup> ; 676.8 ± 9.2								
<b>164d</b> <sup>*</sup>	A549; 0.6 ± 2.9 × 10 <sup>-4</sup>	MCF-7; > 1000		DU-145; 53.6 ± 0.40						
72h	WM2664; 212.2 ± 10.5	HEK-293T <sup>(N)</sup> ; 776.8 ± 15.3								
<b>165</b>	MDA-MB-468; 24.12 ± 1.1			<b>2A</b>		G <sub>2</sub> /M	Mitochondria	320		

<sup>1</sup> IC<sub>50</sub> is defined as the concentration of drug required to inhibit cell growth by 50% compared to the control. Each value represents the mean ± standard deviation from two or three independent experiments.

<sup>2</sup> Cell viability was determined by the MTT assay, other than this is mentioned.

<sup>T</sup>: The complex was examined against normal cell line; <sup>\*</sup>: The complex was safe to the tested normal cell with IC<sub>50</sub> > 100 µM; <sup>N</sup>: Normal cell line; n.d: not determined.

Mechanism of action according to [Fig. 3](#) (within the main text): **1A** pathway: NADH/ROS/MMP/Apoptosis. **1B** pathway: NADH/ROS/LMP/Apoptosis. **1AB** pathway: NADH/ROS/MMP/LMP/Apoptosis. **2A** pathway: ROS/MMP/Apoptosis.

**Full names and Abbreviations of Cell lines:** 16HBE, human bronchial epithelial cell lines; 518A2, human melanoma cell line; 5637, human bladder cancer cells; 8505C, human thyroid carcinoma; ARPE-19, human retinal epithelial cells; A253, human submandibular gland carcinoma; A2780, human ovarian carcinoma cell lines; A2780R/A2780cisR; Cisplatin resistant human ovarian; A427, human lung carcinoma cells; A549, Human lung carcinoma cell line; A549R, cisplatin resistant human lung carcinoma cell line; BEAS-2B, human non-tumorigenic lung epithelial cell line; BEL-7402, human hepatoma cell line; BHK21, normal healthy kidney cells; Caco-2, human colon carcinoma cell lines; Capan2, pancreatic adenocarcinoma cell line; CH1/PA-1, ovarian teratocarcinoma cell lines; CHO, normal Chinese hamster ovarian cells; CHO-K1, Chinese Hamster Ovary-K1 Cells; CNS cancer, Central nervous system cancer; Colo-829, human, umbilical metastasis, melanoma; CRL-2115, human skin fibroblast adherent; CT26, mouse colon carcinoma; DL, Dalton's ascites lymphoma; DLD-1, human colorectal adenocarcinoma cells; DU-145, human prostatic carcinoma; EA.hy926, human umbilical vein endothelial cell line; HaCaT, human keratinocyte cell line; HCT-116, colon cancer cell line; HCT-116 p53<sup>-/-</sup>, colon cancer cell line depleted p53; HEK-293T, human embryonic kidney cell lines; HeLa, cervical cancer cell line; HepG2, human liver cancer cell line; HFF-1, human skin cell lines; HL-60, human leukaemia; HT29, human colorectal adenocarcinoma cells; KMST-6, human skin fibroblast cell line; LCLC-103H, human lung carcinoma cells; LoVo, colorectal adenoma; LO2, human normal liver; MCF-7, human breast cancer cell line; MCF-10, human breast cancer cell lines; MDA-MD-435S, human breast cancer cell lines; MDB-MA-231, human breast cancer cell line; MES-OV, ovarian cancer cells; MIA PaCa-2, pancreatic carcinoma cell lines; MRC-5, human fetal lung fibroblast cells; OVCAR-3, ovarian adenocarcinoma cell line; Panc-1, pancreatic ductular adenocarcinoma cell line; PC3, human prostatic carcinoma; PNT2, normal prostate cell line; Saos, osteosarcoma cell line; SiHa, cervical cancer cell line; SISO, human uterine cervical adenocarcinoma cells; SKOV-3, human ovarian cancer cell line; SW620, human colon cell lines; U87, human glioblastoma cell lines; WHCO1, esophageal cancer cell line; WI-38, human fetal lung fibroblast cells.